Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780243 | 0.78 | TSHR (0.50) | TSHRTP53CA1CA2CA12 | |
| SCHEMBL1303104 | 0.78 | PARP10 (0.43) | TSHRCA1CA2CA12CA9 | |
| SCHEMBL2889295 | 0.78 | HSD17B1 (0.46) | CA5AGAAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL3147633 | 0.78 | ALDH1A1 (0.58) | TSHRTP53SRD5A2MAPTL3MBTL1 | |
| SCHEMBL4957915 | 0.76 | TSHR (0.48) | TSHRTP53CA1CA2CA12 | |
| SCHEMBL185207 | 0.76 | TSHR (0.48) | TSHRTP53CA1CA2CA12 | |
| SCHEMBL1869090 | 0.76 | ALDH1A1 (0.50) | TSHRTP53CA1CA2CA12 | |
| SCHEMBL6631569 | 0.76 | TSHR (0.48) | TSHRTP53CA1CA2CA12 | |
| Terephthalic Acid SCHEMBL5053781 | 0.71 | TSHR (1.00) | TSHRTP53CA1CA2CA12 | |
| Terephthalic Acid SCHEMBL1655 | 0.71 | TSHR (1.00) | TSHRTP53CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176797-A1 | 2-[5-(5-Carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-YL]-succinic acid derivatives as factor viia inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | claimed |
| EP-1408963-A1 | 2- 5-(5-CARBAMIMIDOYL-1 i H /i -HETEROARYL)-6-HYDROXYBIPHENYL-3-YL]-SUCCINIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-04-21 | — | — | EP | claimed |
| US-20030114457-A1 | 2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-06-19 | — | — | US | claimed |
| WO-2003006011-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL]-SUCCINIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| EP-3025763-B1 | CREAM GEL COMPRISING AT LEAST ONE RETINOID AND BENZOYL PEROXIDE | GALDERMA RES & DEV (FR) | 2020-06-10 | — | — | EP | disclosed |
| EP-3355858-B1 | NO-RINSE CHEMICAL FOAM CONTAINING BRIMONIDINE, AND USE THEREOF IN THE TREATMENT OF ROSACEA | GALDERMA RES & DEV (FR) | 2020-03-18 | — | — | EP | disclosed |
| EP-3355867-B1 | NO-RINSE CHEMICAL FOAM COMPRISING IVERMECTIN | GALDERMA RES & DEV (FR) | 2020-03-18 | — | — | EP | disclosed |
| EP-3355866-B1 | SELF-FOAMING CLEANSING COMPOSITION CONTAINING CLOBETASOL PROPIONATE, AND USE THEREOF IN THE TREATMENT OF PSORIASIS | GALDERMA RES & DEV (FR) | 2020-03-18 | — | — | EP | disclosed |
| EP-3355869-B1 | RINSE-OFF SELF-FOAMING CLEANSING COMPOSITION CONTAINING IVERMECTIN | GALDERMA RES & DEV (FR) | 2020-03-18 | — | — | EP | disclosed |
| EP-3355868-B1 | NO-RINSE CHEMICAL FOAM CONTAINING CLOBETASOL PROPIONATE, AND USE THEREOF IN THE TREATMENT OF PSORIASIS | GALDERMA RES & DEV (FR) | 2020-03-11 | — | — | EP | disclosed |
| CN-108017577-B | The process for catalytic synthesis of 2- pyridone | 怀化学院 | 2019-03-01 | — | — | CN | disclosed |
| EP-3122325-B1 | UNRINSED CHEMICAL FOAMCONTAINING BENZOYL PEROXIDE | GALDERMA RES & DEV (FR) | 2018-10-31 | — | — | EP | disclosed |
| EP-0460550-B1 | Silver halide photographic material | FUJI PHOTO FILM CO LTD (JP) | 1997-08-06 | — | — | EP | disclosed |
| US-5643932-A | PREVENTS CELL DAMAGE AFTER ISCHEMIA AND RE-PERFUSION, SUBSTITUTED THIAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0513387-A1 | ACTIVE OXYGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | disclosed |
| EP-0460550-A1 | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1991-12-11 | — | — | EP | disclosed |
| US-4853328-A | Reagent for assaying hydrogen peroxide and method of quantitative assay for hydrogen peroxide | FUJI PHOTO FILM CO., LTD. (JP) | 1989-08-01 | — | — | US | disclosed |
| EP-0060518-B2 | REAGENT FOR ASSAYING HYDROGEN PEROXIDE AND METHOD OF QUANTITATIVE ASSAY FOR HYDROGEN PEROXIDE | FUJI PHOTO FILM CO., LTD. (JP) | 1988-09-21 | — | — | EP | disclosed |
| EP-0060518-B1 | REAGENT FOR ASSAYING HYDROGEN PEROXIDE AND METHOD OF QUANTITATIVE ASSAY FOR HYDROGEN PEROXIDE | FUJI PHOTO FILM CO., LTD. (JP) | 1985-07-17 | — | — | EP | disclosed |
| EP-0060518-A1 | Reagent for assaying hydrogen peroxide and method of quantitative assay for hydrogen peroxide | FUJI PHOTO FILM CO., LTD. (JP) | 1982-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114457-A1 | 2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors | F7, F9, F5 | TSHR 4118/4885TP53 4795/4885CA1 1477/4885 |
| US-20050176797-A1 | 2-[5-(5-Carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-YL]-succinic acid derivatives as factor viia inhibitors | F7, F9, F5 | TSHR 4118/4885TP53 4795/4885CA1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.